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a  b  s  t r  a  c  t
This work  investigated  the  modulation  by  melatonin  (Mel)  of  the  effects  of  the  porphyrinogenic
drugs  2-allyl-2-isopropylacetamide  (AIA)  and  3,5-diethoxycarbonyl-1,4-dihydro-2,4,6-collidine  (DDC)
on oxidative  environment,  glucose  biosynthesis  and  heme  pathway  parameters.  Administration  of  Mel
before  rat  intoxication  with  AIA/DDC  showed  a clear  beneﬁcial  effect  in all cases.  Mel  induced  decreases
of  42%  and  35%  in  the  excretion  of  the  hemeprecursors  5-aminolevulinic  acid  (ALA) and porphobilinogen
(PBG),  respectively,  and  a 33%  decrease  in  the  induction  of the heme  regulatory  enzyme  5-aminolevulinic
acid-synthase  (ALA-S).  The  activity  of  the glucose  metabolism  enzyme  phosphoenolpyruvate  carboxyki-
nase  (PEPCK),  which  had been  diminished  by  the  porphyrinogenic  treatment,  was  restored  by 45% when
animals  were  pre-treated  with  Mel.  Mel  abolished  the  modest  decrease  in glucose  6-phospatase  (G6Pase)
activity  caused  by  AIA/DDC  treatment.  The  oxidative  status  of lipids  was  attenuated  by  Mel  treatment
in  homogenates  by  47%,  whereas  no  statistically  signiﬁcant  AIA/DDC-induced  increase  in thiobarbituric
acid  reactive  substances  (TBARS)  was  observed  in  microsomes  after  Mel  pre-treatment.  We  hypothe-
size that Mel  may  be  scavenging  reactive  species  of  oxygen  (ROS)  that  could  be  damaging  lipids,  PEPCK,
G6Pase  and  ferrochelatase  (FQ).  Additionally,  Mel  administration  resulted  in  the  repression  of the  key
enzyme  ALA-S,  and  this  could  be  due  to  an  increase  in  glucose  levels,  which  is known  to inhibit  ALA-Seywords:
elatonin
lucose synthesis
eme pathway
cute porphyria
induction.  The  consequent  decrease  in  levels  of the  heme  precursors  ALA  and  PBG had  a  beneﬁcial  effect
on  the  drug-induced  porphyria.  The  results  obtained  open  the  possibility  of further  research  on  the  use
of  melatonin  as  a co-treatment  option  in  acute  porphyria.
©  2016  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is an open  access  article  under  the CC
BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).xidative stress
. Introduction
Melatonin (Mel), which derives from the serotoninergic path-
ay of tryptophan, is a neurohormone with antioxidant properties
28]. It is mainly produced in the pineal gland but also in other
rgans. Mel  has a number of physiological effects including the reg-
lation of circadian rhythms, oncostasis, stimulation of the immune
ystem and the regeneration of sexual activity, as well as being anti-
nﬂammatory [8]. Mel  has been identiﬁed as a powerful direct free
adical scavenger and an antioxidant of broad spectrum even more
otent than glutation (GSH). It can cross the hemato-encephalic and
lacental barriers [32,29]. Numerous investigations have shown its
bility to reduce the molecular damage caused by reactive species
f oxygen (ROS) and reactive nitrogen species (RNS) [8]).
∗ Corresponding author. Fax: +54 11 45763342.
E-mail address: dimxsa@qb.fcen.uba.ar (L.C. San Martín de Viale).
1 MBM  and LCSMV contributed equally to this work.
ttp://dx.doi.org/10.1016/j.toxrep.2015.12.010
214-7500/© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access
c-nd/4.0/).Porphyrias are hereditary disorders caused by a de-regulation
of the heme pathway due to deﬁciencies in the activity of some
of its enzymes, which lead to the accumulation of heme precursors
and diminished heme formation. This deﬁciency triggers the induc-
tion of the regulatory enzyme 5-aminolevulinic acid-synthase
(ALA-S) [3]. Life-threatening acute porphyrias are biochemically
characterized by the accumulation of heme precursors such as
5-aminolevulinic acid (ALA), which promotes oxidative stress by
generating ROS [3,6].
The porphyrinogenic drug 2-allyl-2-isopropylacetamide (AIA)
enhances the destruction of liver heme, particularly cytochrome
P-450, whereas the porphyrinogenic drug 3,5-diethoxycarbonyl-
1,4-dihydro-2,4,6-collidine (DDC) strongly depletes heme by
combination of heme destruction and inhibition of heme synthe-
sis [18]. AIA/DDC treatment results in acute heme deﬁciency, an
impairment of ferrochelatase (FQ) activity, a marked de-repression
of ALA-S and, as a consequence, an exacerbated production of ALA
and other heme precursors in the liver [14]. This combined treat-
ment has been reported to induce a rat experimental porphyria
 article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
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esembling quite accurately acute variegate porphyria [14]. Accu-
ulated ALA has been associated with iron-mediated oxidative
amage to biomolecules and cell structures through ROS gener-
tion [6]. ROS are able to oxidize nucleic acids, proteins, lipids,
nd carbohydrates, affecting key cellular functions [6]. It has been
emonstrated that AIA/DDC treatment promotes the establishment
f an oxidative environment with increases in ROS [14].
Glucose administration is known to have beneﬁcial effects
n acute porphyria patients, signiﬁcatively improving biochem-
cal parameters and clinical conditions [3]. The prevention of
cute experimental porphyria through a carbohydrate-rich diet
n animal models illustrates the effect of glucose, which pre-
ents the induction of the heme pathway regulatory enzyme
LA-S [33]. Furthermore, it has been reported that treatment with
IA/DDC hinders gluconeogenesis and glycogenolysis leading to
 reduction in glucose availability in hepatocytes. In particular,
epatic phosphoenolpyruvate carboxykinase (PEPCK) and glyco-
en phosphorylase (GP) activities have been found impaired in
IA/DDC-induced rat porphyria [14,20].
The relationship between carbohydrates and oxidative status
ith porphyria, plus the known anti-oxidant and radical-
cavenging properties of Mel, prompted the present investigation
bout Mel  as a possible modulator of AIA/DC-induced experimental
orphyria. Effects were studied at the level of oxidative environ-
ent, glucose biosynthesis and heme pathway by measuring key
nzymes of the heme and glucose pathways as well as porphyria
nd lipid peroxidation markers.
. Materials and methods
.1. Materials
AIA was a gift from Roche Co. (Germany). DDC was purchased
rom Aldrich Chemical Company Inc. (Milwaukee, WI). Melatonin,
ovine serum albumin, deoxyguanosine 5′-diphosphate, glucose-
-phosphate, malate dehydrogenase, NADH, Dowex 1, Dowex 50 W
nd thiobarbituric acid were obtained from Sigma Chemical Co. (St.
ouis, MO). All other chemicals were of analytical grade.
.2. Animal treatments
Female Wistar rats (180–200 g) were purchased from the
ational Committee of Atomic Energy (CONEA, Argentina). They
ere maintained on food and water ad libitum and housed
nder conditions of controlled temperature (25 ◦C) and light (12 h
ight–dark cycle, light from 6am to 6pm).
Animals were treated according to International Guidelines
Guide for Care and Use of Laboratory Animals, National Research
ouncil, USA, 1996, the Council of the European Communities
irective, 86/609/ECC) and to guidelines from the Animal Care
nd Use Committee of the Argentine Association of Specialists in
aboratory Animals (AADEALC). AIA was dissolved in saline solu-
ion (0.9% NaCl, w/v) and DDC was dissolved in corn oil [5] just
efore administration. Melatonin was dissolved in pure ethanol.
he solution was  protected from light and kept at 4 ◦C until injec-
ion. Ethanolic stocks were diluted with 0.9% NaCl (w/v) to achieve
 ratio 0.9% NaCl/ethanol of 20/1 (v/v, melatonin vehicle). Mel  was
issolved in saline just before being ip administered.
A total of 3 experiments were performed, each involving 8 ran-
omly selected animals divided in 4 groups of 2 animals. The four
roups were as follows: “−Mel,−AIA/DDC”, not pretreated with
el  nor treated with AIA/DDC; “−Mel,+AIA/DDC”, not pretreated
ith Mel  and treated with AIA/DDC; “+Mel,−AIA/DDC”, pretreated
ith Mel  but not treated with AIA/DDC; and “+Mel,+AIA/DDC”, pre-
reated with Mel  and then treated with AIA/DDC. Mel  (10 mg/kg)ports 3 (2016) 141–147
body weight (bw) or Mel  vehicle were intraperitoneally (ip)
injected 3 times a day at 8am, 12pm and 4pm during 2 days. At the
end of this treatment, intoxication with AIA (300 mg/kg), bw,  sub-
cutaneously (sc) and DDC (50 mg/kg bw,  ip) was performed. In the
case of controls, Mel, AIA and DDC vehicles were administered. Mel
dosage was based on studies about its drug toxicity-reduction and
drug protective ability [27,11,13]. Rats were fasted 8 h before and
16 h after intoxication. Access to drinking water was free. Param-
eters were measured in duplicate at 16 h post-intoxication, in all
cases. Urine was collected during the whole period of 16 h after
intoxication by using individual metabolic cages for each animal.
2.3. Liver extracts
Rats were euthanized by carbon dioxide inhalation followed by
decapitation, 16 h after AIA/DDC administration. Animals had been
fasted for a total of 24 h before death, as this has been previously
shown to result in reliable measurements of PEPCK and glucose 6-
phospatase (G6Pase) activities [22]. Livers previously perfused with
ice-cold saline solution, were removed and portions from them
were homogenized in a Potter-Elvehjem homogenizer using differ-
ent solutions according to the assays to be performed, in all cases
at 0–4 ◦C. Liver portions of approximately 1 g were excised and
immediately homogenized in 3 ml  of a solution containing 0.9%
NaCl, 0.1 mM Tris–HCl pH 7.4 and 0.5 mM  EDTA. These extracts
were employed to determine ALA-S activity [19]. For PEPCK activity,
liver was  homogenized (1:3 w/v) in 0.25 M sucrose. Homogenates
were centrifuged for 1 h at 100000xg and the resulting super-
natants were used for PEPCK activity measurements while the
pellets, properly resuspended, were used for microsomal G6Pase
enzymatic determination. All procedures were carried out at 4 ◦C.
For hepatic FQ determination, homogenates were prepared with
0.154 M KCl (1:5 w/v). Homogenates were centrifuged for 25 mim
at 11000xg and the resulting pellets were frozen until hepatic FQ
activities were determined. Lipid peroxidation was determined in
homogenates (those used also for PEPCK activity tissue prepa-
rations) and microsomal fractions (those used also for G6Pase
enzymatic determination)
2.4. Metabolite levels and enzyme assays
2.4.1. 5-Aminolevulinic acid and porphobilinogen in urine
0.3–1.0 ml  samples from urine collected during 16 h after intoxi-
cation adjusted to pH 4.5–6.0, was  placed on the top of two column,
anion–cation exchange assembly as described by Piper et al. [25].
Then the column assembly was washed three time with 8 ml  of
distilled water and then the columns were separated. PBG, bound
to the anion exchange Dowex 1 column, was eluted by 2 ml of
1 M acetic acid followed by 3 ml  of 0.2 M acetic acid, whereas ALA
bound to the cation exchange Dowex 50W column was  eluted with
7 ml  of 1 M sodium acetate. ALA pyrrole and PBG were determined
colorimetrically as described by Mauzerall and Granick [21].
2.4.2. 5-Aminolevulinic acid synthase activity
ALA-S activity was assayed in whole liver homogenates by the
method of Marver et al. [19]. Incubation mixtures containing 0.1 M
glycine, 0.01 M EDTA, 0.08 M Tris–HCl buffer pH 7.2 and 0.5 ml  of
homogenate in a ﬁnal volume of 2 ml  were incubated at 37 ◦C for
60 min. The reaction products were determined spectrophotomet-
rically at 553 nm [21].2.4.3. Ferrochelatase activity
FQ activities were measured in liver mitochondrial fractions.
Pellets containing mitochondria were used after being frozen
at −20 ◦C for 24–48 h. Enzymatic activities were determined in
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esuspended pellets, using protoporphyrin IX as substrate, as
escribed by Porra and Jones [26].
.4.4. Phosphoenolpyruvate carboxykinase activity
PEPCK was measured according to Petrescu et al. [24] using
eoxyguanosine 5′-diphosphate as the substrate, and 100,000 × g
omogenate supernatant of as the enzyme source (Section 2.3).
he oxaloacetate formed during the reaction was  determined
pectrophotometrically at 340 nm by reduction with malate dehy-
rogenase in the presence of NADH.
.4.5. Glucose 6-phosphatase activity
G6-Pase was measured as described by Baginski et al. [2].
he release of inorganic phosphate from glucose-6-phosphate
as measured through the formation of the phosphomolybdate
omplex and its reduction by ascorbic acid, which is quantiﬁed
pectrophotometrically at 700 nm [1]. Pellets obtained from liver
omogenates, containing approximately 40 g protein, were used
s the source of enzyme activity, as described in Section 2.3.
.4.6. Lipid peroxidation
Lipid peroxidation was determined by measuring the rate
f generation of thiobarbituric acid reactive substances (TBARS)
sing whole homogenates and microsomes from liver. The red
alonyldialdehyde–thiobarbituric acid complex produced was
xtracted with butanol to avoid interference by endogenous por-
hyrins. TBARS content was measured by its absorbance at 532 nm,
sing the molar absorption coefﬁcient 156,000 M−1 cm−1 [23].
.4.7. Protein determination
Protein concentrations were measured according to Lowry et al.
16] using bovine serum albumin as standard.
.5. Statistical analysis
Figure data are expressed as means (±SEM) of six animals,
.e. combining together the animals of the same group from all
hree experiments. Data were subjected to analysis of variance
ANOVA) with two factors: Mel  pre-treatment and AIA/DDC treat-
ent. Multiple comparisons among groups were performed using
ukey–Kramer’s test. Differences were considered signiﬁcant when
 < 0.05. Before statistical analysis, data were tested for normal-
ty and uniformity of variance using Lilliefors and Bartlett’s tests,
espectively.
. Results
.1. Heme pathway parameters
The levels of total urinary excretion of ALA and PBG indi-
ate the severity of porphyric conditions. The porphyrinogenic
IA/DDC treatment induced statistically signiﬁcant increases of
37% for ALA and 356% for PBG, in the absence of melatonin pre-
reatment (“−Mel,+AIA/DDC” vs “−Mel,−AIA/DDC”, Fig. 1A and B).
el  pre-treatment resulted in a 25% decrease (p < 0.05) in the total
mount of ALA formed under drug treatment (“−Mel,+AIA/DDC”
s “+Mel,+AIA/DDC”, Fig. 1A). A comparison of the drug-induced
LA increases in the absence of Mel  (“−Mel,+AIA/DDC” vs
−Mel,−AIA/DDC”, Fig. 1A) with those in the presence of Mel
“+Mel,+AIA/DDC” vs “+Mel,−AIA/DDC”, Fig. 1A), a Mel-induced
ecrease of 42% (p < 0.05) in ALA accumulation is apparent. The
otal amount of PBG formed after drug treatment was smaller by
8% (p < 0.05) as a result of Mel  pre-treatment (“+Mel,+AIA/DDC”
s “−Mel,−AIA/DDC”, Fig. 1B). A comparison of the drug-induced
BG increases in the absence of Mel  (“−Mel,+AIA/DDC” vs
−Mel,−AIA/DDC”, Fig. 1B) with those in the presence of Melorts 3 (2016) 141–147 143
(“+Mel,+AIA/DDC” vs “+Mel,−AIA/DDC”, Fig. 1B) shows that a Mel-
induced decrease of 35% (p < 0.05) in PBG accumulation is apparent.
Even in the absence of porphyrinogenic drugs, Mel  treatment
resulted in a decrease of 36% (p < 0.05) in PBG levels, shown by
comparing the groups “−Mel,−AIA/DDC” and “+Mel,−AIA/DDC”
(Fig. 1B).
The activity of the heme pathway enzyme ALA-S was  enhanced
by 326% (p<0.05) as a result of the porphyrinogenic treatment
(“−Mel,+AIA/DDC” vs “−Mel,−AIA/DDC”, Fig. 2A). When animals
were pre-treated with Mel  before administration of AIA/DDC, ALA-
S activity increased much less, by 220% (p < 0.05) (“+Mel,+AIA/DDC”
vs “+Mel,−AIA/DDC”, Fig. 2A). In brief, Mel  attenuated by 33% the
drug-induced enhancement of ALA-S activity. Mel  alone had no
effect on the expression of ALA-S activity (“+Mel,−AIA/DDC” vs
“−Mel,−AIA/DDC”, Fig. 2A).
Because FQ is the last enzyme of the heme pathway, decreases
in its activity will favor porphyria, inversely to ALA-S. As
expected, FQ activity was  decreased by 71% (p < 0.05) as a result
of AIA/DDC treatment (“−Mel,+AIA/DDC” vs “−Mel,−AIA/DDC”,
Fig. 2B). This reduction was essentially the same when ani-
mals were pre-treated with Mel, as shown by comparing the
decrease of “+Mel,+AIA/DDC” vs “+Mel,−AIA/DDC” with that of
“−Mel,+AIA/DDC” vs “−Mel,−AIA/DDC” (Fig. 2B). Mel  alone did not
affect FQ activity (“+Mel,−AIA/DDC” vs “−Mel,−AIA/DDC”, Fig. 2B).
3.2. Gluconeogenesis parameters
Since glucose is known to be beneﬁcial to acute porphyr-
ias, we determined the hepatic activity of the gluconeogenic
enzymes PEPCK and G6Pase in the four groups studied (Fig. 3).
Porphyrinogenic treatment resulted in a 55% decrease (p < 0.05)
in PEPCK activity, as can be seen comparing “−Mel,+AIA/DDC”
with “−Mel,−AIA/DDC” (Fig. 3A). Administration of Mel  before
AIA/DDC reverted by 45% (p < 0.05) this porphyrinogenic drug-
induced decrease in PEPCK, as shown by comparing the
difference between “+Mel,+AIA/DDC” and “−Mel,+AIA/DDC” with
the decrease “−Mel,+AIA/DDC” vs “−Mel,−AIA/DDC” (Fig. 3A).
G6Pase activity was 15% lower (p < 0.05) in porphyric animals
(“−Mel,+AIA/DDC” vs “−Mel,−AIA/DDC”, Fig. 3B), and Mel  pre-
treatment abolished the difference between AIA/DDC-treated and
untreated rats (“+Mel,+AIA/DDC” vs “+Mel,−AIA/DDC”, Fig. 3B). The
administration of Mel  alone did not alter the activity of either PEPCK
or G6Pase in a statistically signiﬁcant way (“+Mel,−AIA/DDC” vs
“−Mel,−AIA/DDC”, Fig. 3A and B).
3.3. Oxidative stress
The development of AIA/DDC-induced oxidative stress was
followed by determining TBARS levels in homogenates (Fig. 4A)
and microsomes (Fig. 4B) from livers, in the four different
animal groups. Porphyric rats showed increases in TBARS
both in homogenates (45%, p < 0.05) and microsomes (21%
p < 0.05), as shown by the comparison “−Mel,+AIA/DDC” with
“−Mel,−AIA/DDC” (Fig. 4A). Pre-treatment with Mel  resulted in
a considerably smaller increase in TBARS (24% p < 0.05) in liver
homogenates, apparent when comparing “−Mel,+AIA/DDC” with
“+Mel,+AIA/DDC” (Fig. 4A). The increase in TBARS generation
due to AIA/DDC in the absence of Mel  (“−Mel,+AIA/DDC” vs
“−Mel,−AIA/DDC”, Fig. 4A) was  reduced by 47% in its presence
(“+Mel,+AIA/DDC” vs “+Mel,−AIA/DDC”, Fig. 4A). In micro-
somes, pre-treatment with Mel  abolished the 21% increase
(p < 0.05) in TBARS induced by AIA/DDC without Mel  (compare
“−Mel,+AIA/DDC” vs “−Mel,+AIA/DDC” with “+Mel,−AIA/DDC”
vs “+Mel,+AIA/DDC”, Fig. 4B). Mel  alone did not affect lipid
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Fig. 1. Levels of the heme pathway metabolites ALA (A) and PBG (B) in urine: effect of melatonin pre-treatment on AIA/DDC-induced porphyrinogenesis.
ALA  and PBG levels were determined in liver extracts from animals belonging to four different groups: −Mel−AIA/DDC, not pretreated with Mel  nor treated with AIA/DDC;
−Mel+AIA/DDC, not pretreated with Mel  and treated with AIA/DDC; +Mel −AIA/DDC, pretreated with Mel but not treated with AIA/DDC; and +Mel + AIA/DDC, pretreated with
Mel  and then treated with AIA/DDC. Results are expressed as means ± SEM (n = 6 for each group). Urinary ALA content value of “−Mel−AIA/DDC” group: 6 g ALA/16 h; urinary
PBG  content value of “−Mel−AIA/DDC”group: 1.93 mg/16 h. Statistically signiﬁcant differences between groups (p<0.05) are indicated by asterisks above horizontal lines
showing the group comparisons, as follows: “−Mel,+AIA/DDC” compared with “−Mel,−AIA/DDC”, for both ALA and PBG; “+Mel,+AIA/DDC” compared with “+Mel,−AIA/DDC”,
for  both ALA and PBG; “+Mel,+AIA/DDC” compared with “−Mel,+AIA/DDC”, for both ALA and PBG; “+Mel,−AIA/DDC” compared with “−Mel,−AIA/DDC”, for PBG
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. DiscussionWe  report here that the administration of Mel  prior to the intox-
cation of rats with AIA/DDC results in a clear beneﬁcial effect on the
epatic alterations elicited by these porphyrinogenic drugs regard-
ng heme pathway, glucose metabolism and lipid peroxidation.n groups (p < 0.05) are indicated by asterisks above horizontal lines showing the
r ALA-S and FQ; “+Mel,+AIA/DDC” compared with “−Mel,+AIA/DDC”, for ALA-S;
The AIA/DDC-induced increase in peroxidation we are report-
ing, indicated by an increase in TBARS in both liver homogenates
and microsomes, is in agreement with increases previously
found in our laboratory concerning protein carbonyl content,
urinary chemiluminiscence, antioxidant SOD responses [14] and
8-hydroxy-2′-deoxyguanosine levels in urine [6]. These results,
all obtained using the same porphyrinogenic drugs and rat
strain, conﬁrm the existence of oxidative stress in this exper-
imental model of acute porphyria. The mechanism involves an
important drug-induced increase in ALA-S activity causing the
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compared with “−Mel,−AIA/DDC”, for PEPCK and G6Pase; “+Mel,+AIA/DDC” compared with “−Mel,+AIA/DDC”, for PEPCK; “+Mel,+AIA/DDC” compared with “+Mel,−AIA/DDC”,
for  PEPCK.
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Fig. 4. Oxidative stress: effect of melatonin pre-treatment on AIA/DDC-induced porphyrinogenesis.
As  markers of lipid peroxidation, levels of thiobarbituric acid reactive substances (TBARS) were determined in liver homogenates (A) and microsomal fractions (B) of animals
belonging to the four different groups described in Section 2.2 and Fig. 1.
Results are expressed as means ± SEM (n = 6 for each group). Hepatic TBARS homogenate value of “−Mel−AIA/DDC” group: 228 nmoles MDA/g liver.h; hepatic TBARS
microsomes value of “−Mel−AIA/DDC” group: 20 nmoles MDA/mg prot.h.
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ccumulation of ALA, which in turn promotes an oxidative envi-
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amage lipids, DNA and proteins. The fact that the extent of the
rug-induced oxidative level is reduced as a consequence of pre-
reatment of the animals with Mel  is likely to be due to the
ntioxidant and free radical scavenging properties of this hor-
one. Mel  has been reported to interact with highly toxic hydroxyl
adicals and neutralize hydrogen peroxide, singlet oxygen, perox-
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interactions of Mel  with ROS via oxidative pyrrole ring cleavage
can generate further antioxidant compounds such as cyclic 3-
hydroxymelatonin, N1-acetyl-N2-formyl-5-methoxyquinuramine
(AFMK) and N1-acetyl-5-methoxyquinuramine (AMK) [29,30]. The
process by which Mel  and its metabolites scavenge ROS and RNS
is considered to be a free radical scavenging cascade that magni-
ﬁes the efﬁcacy of Mel  as an antioxidant [8]. The ability of Mel  to
attenuate lipid damage, here described, is in keeping with reports
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f Mel  decreasing lipid peroxidation and the rigidity of microsomal
embranes due to the oxidative stress caused by ALA [12].
Aldehydes generated during lipid peroxidation can react with
mino-acid side chains of proteins [4], with the residues suscep-
ible to oxidation being Arg, Lys, Thr, Cys and His [15]. Therefore,
OS generated during the porphyrinogenic treatment could dam-
ge protein structures and/or even oxidize enzyme active site
esidues. Thus, the activity of gluconeogenic enzymes such as
EPCK and G6Pase can be reduced by AIA/DDC treatment [14],
o favoring the development of acute porphyria. In fact, G6Pase
s a nine-transmembrane domain protein with a catalytic center
ncluding Lys76, Arg83, His119, Arg170, and His176 on the luminal
ide of the ER membrane. His176 is involved in the formation of
 phosphohistidine-enzyme intermediate during catalysis [9,10].
re-treatment with Mel  had attenuating, beneﬁcial effects regard-
ng PEPCK and G6Pase activities.
Summarizing, the AIA/DDC-induced decrease in the activity of
he gluconeogenic enzymes PEPCK and G6Pase results in a reduc-
ion in glucose synthesis. The latter de-represses the regulatory
eme pathway enzyme ALA-S [33], as shown in the present work
nd in agreement with our previous ﬁndings [14,20]. Pre-treatment
ith Mel  partially reverts the AIA/DDC-induced decreases in PEPCK
nd G6Pase activities, therefore increasing glucose synthesis. As a
onsequence, ALA-S is repressed. The down-regulation of ALA-S
as conﬁrmed in the present work by the observed decrease in
evels of the heme precursors ALA and PBG elicited by Mel  pre-
reatment. Being the last enzyme for heme synthesis, a lower FQ
ctivity favors the accumulation of heme precursors. We  observed
 lower FQ activity in AIA/DDC-treated rats, probably due to oxida-
ive reactions affecting SH groups [31] and an essential His residue
eemingly involved in Fe+2 chelation [7]. The porphyrinogenic
rug-induced decrease in FQ activity was not reversed by Mel  pre-
reatment.
The inﬂuence of Mel  pre-treatment on the events described
bove point to a beneﬁcial decrease in the severity of acute por-
hyria in the model here employed. This is in line with other
eneﬁcial effects reported for Mel  in a broad number of different
ituations [17]. The results shown also suggest the possibility of
sing Mel  as co-treatment for acute porphyria.
. Conclusions
The present work shows that Mel  treatment has a beneﬁcial
ffect in experimental acute porphyria. We  hypothesize that Mel
ould be scavenging ROS/RNS that peroxidize lipids and alter PEPCK
nd G6Pase activity. Mel  would act by restoring glucose levels,
herefore repressing ALA-S, with a consequential decrease in the
evels of the heme precursors ALA and PBG which decreases the
everity of porphyria. The results obtained open new research pos-
ibilities regarding the use of melatonin as a co-treatment option
n acute porphyria.
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